Skip to main content

Security report for biogen.com.au

Biogen Australia Pty Ltd · Healthcare · Australia

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Australia Pty Ltd operates as a leading biotechnology company focused on pioneering scientific innovations for complex diseases, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. The company positions itself as a global leader with a strong commitment to serving humanity through science, advancing health, sustainability, and equity. The website targets healthcare professionals, patients, and potential employees, offering detailed information about disease areas, medicines, corporate responsibility, and career opportunities. Technically, the website is built on Adobe Experience Manager CMS, utilizing modern JavaScript libraries such as jQuery and Adobe Helix RUM for performance monitoring. It implements cookie consent via Cookiebot and uses Google Tag Manager for analytics. The site is mobile-optimized with good SEO practices and a professional design, though accessibility features are basic. From a security perspective, the site enforces HTTPS and includes cookie consent mechanisms, but lacks visible security headers and published security policies or incident response contacts. No vulnerabilities or exposed sensitive data were detected in the HTML content. WHOIS data is privacy protected, which is typical for large enterprises, though it limits transparency. Overall, the site demonstrates a solid security posture but could improve transparency and security best practices. The overall risk assessment is low, with recommendations to publish security policies, enhance security headers, and provide incident response contacts to improve trust and compliance. The site is professional, trustworthy, and well-maintained, supporting Biogen's market position as a leading biotechnology company.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.com.au

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen Australia operates in the healthcare biotechnology sector with a focus on neurological and rare diseases. The company leverages scientific research and innovation to develop therapies, targeting a global market with localized presence in Australia. Its business model centers on R&D and commercialization of specialty medicines. The website reflects a mature digital presence with comprehensive content for multiple stakeholders including healthcare professionals and job seekers. The company maintains a strong brand with consistent messaging and global partnerships indicated by multiple regional domains. The absence of direct contact emails but presence of contact forms suggests controlled communication channels. Certifications and social media presence enhance credibility. Growth indicators include active career pages and innovation highlights. The partnership ecosystem is global, with multiple country-specific domains linked.

Security posture

The website demonstrates a moderate to strong security posture with enforced HTTPS and cookie consent mechanisms. However, it lacks explicit security headers such as Content-Security-Policy and X-Content-Type-Options, which are recommended to mitigate common web vulnerabilities. No security policy or incident response information is publicly available, which could hinder transparency and user trust. The absence of vulnerability disclosure programs or security.txt files indicates room for improvement in security communication. No exposed sensitive data or vulnerable libraries were detected. Overall, the site is secure but could benefit from enhanced security best practices and published policies to align with industry standards and compliance requirements.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and commitments.
  2. Implement and configure security headers including Content-Security-Policy, X-Content-Type-Options, and Strict-Transport-Security.
  3. Provide clear incident response contact information to facilitate reporting and handling of security incidents.
  4. Establish a vulnerability disclosure program or security.txt file to encourage responsible reporting of security issues.
  5. Regularly audit and update third-party libraries and scripts to mitigate potential vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Australia Pty Ltd
Description
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialised immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Key services
Neurology therapies, Neuropsychiatry therapies, Specialized immunology therapies, Rare disease therapies
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Tag Manager, Adobe Helix RUM
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot session tracker
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professionally presented and relevant to biotechnology and healthcare.
  3. Comprehensive cookie and privacy policies with consent mechanisms are implemented.
  4. WHOIS data is privacy protected, limiting domain ownership transparency.
  5. No direct contact emails or phone numbers found; contact is via form.
  6. Social media presence is strong with official accounts linked.
  7. No security policy or incident response information publicly available.
  8. No vulnerability disclosure or security.txt found.
  9. Website uses modern technologies and Adobe Experience Manager CMS.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, indicating a robust enterprise-grade content management platform. It uses modern JavaScript libraries such as jQuery 3.6.4 and Adobe Helix RUM for real user monitoring. Cookiebot is integrated for cookie consent management, and Google Tag Manager is used for analytics and marketing tags. The site is mobile responsive with good SEO metadata including Open Graph and Twitter Card tags. Performance is moderate, with video content and images optimized for different devices. Accessibility features are basic but present. No major technical debt or deprecated technologies were detected. Hosting provider details are not explicit but likely enterprise-grade given the CMS and domain profile.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.com.au. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.com.au.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.